Form 8-K - Current report:
SEC Accession No. 0001564590-21-043448
Filing Date
2021-08-11
Accepted
2021-08-11 16:17:07
Documents
14
Period of Report
2021-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pcvx-8k_20210811.htm   iXBRL 8-K 45073
2 EX-99.1 pcvx-ex991_6.htm EX-99.1 282696
3 GRAPHIC g2fe4eiholgi000001.jpg GRAPHIC 40175
  Complete submission text file 0001564590-21-043448.txt   527342

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA pcvx-20210811.xsd EX-101.SCH 5772
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pcvx-20210811_lab.xml EX-101.LAB 19461
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pcvx-20210811_pre.xml EX-101.PRE 11628
7 EXTRACTED XBRL INSTANCE DOCUMENT pcvx-8k_20210811_htm.xml XML 3540
Mailing Address 353 HATCH DR FOSTER CITY CA 94404
Business Address 353 HATCH DR FOSTER CITY CA 94404 650-837-0111
Vaxcyte, Inc. (Filer) CIK: 0001649094 (see all company filings)

EIN.: 464233385 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39323 | Film No.: 211163638
SIC: 2836 Biological Products, (No Diagnostic Substances)